Generex Biotechnology Announces the Launch of a New Corporate Website

- www.generex.com
- Life Science Holdings Corporate Strategy
- New organizational structure with the NuGenerex Family of subsidiary companies
- Management Team

MIRAMAR, FL, January 7, 2019/PRNewswire/ -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. You can visit the site at www.generex.com.

Generex has reorganized its portfolio of immuno-oncology assets, medical devices, and diagnostics as a family of NuGenerex subsidiary companies, and expanded the business focus through acquisitions of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization (MSO) with a network of over 400 physicians and expansion opportunities from 5 to 27 states, a network of pharmacies across the U.S., a clinical laboratory with specialty diagnostic services, and two regenerative medicine companies, Regentys and Olaregen that have been announced this week.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

“We have worked diligently over the last two years on this considerable reorganization, and we are proud to share the results of our efforts and our vision for the future of Generex Biotechnology as a healthcare holding company that adds significant value for our shareholders and investors,” said Joe Moscato, CEO of Generex. “We have organized our businesses as independently operating subsidiaries under the umbrella of the NuGenerex Family of Companies, highlighting the intra-company synergies that allow for cross-company business and integrated sales. Further, we are acquiring companies like Regentys and Olaregen that fit with our strategic model to provide end-to-end solutions for patients and doctors. As you will see when you visit the site, we have transformed Generex into a new kind of healthcare company, with proprietary
products and service lines that drive revenue to support the clinical development of innovative therapies and value for our investors.”

**About Generex Biotechnology Corp.**

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

**Cautionary Note Regarding Forward-Looking Statements**

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato
646-599-6222

Todd Falls
800-391-6755 Extension 222

investor@generex.com